Dr Jennifer Rosenthal Appointed Clarity Pharmaceuticals Director of Quality and Regulatory Affairs

23 October 2019

Sydney, Australia – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Jennifer Rosenthal as Director of Quality and Regulatory Affairs.

Jennifer has more than 20 years’ management experience in the biotechnology industry, serving in senior director and executive level roles with an oncology focus.  She has successfully developed strategy, and managed teams and projects in the areas of regulatory affairs (FDA, EMA, TGA), clinical trials, quality assurance and intellectual property.

Jennifer joins Clarity from Viralytics Limited where she has been managing the global regulatory team, developing strategy and quality systems for 4 years. Viralytics was an ASX listed biotechnology company before being acquired by Merck & Co for AUD$502 million in 2018, which was the largest transaction in the Australian biotech sector for an R&D stage company. Jennifer was a key member of the due diligence team for Viralytics during the acquisition.

Prior to Viralytics, Jennifer spent 10 years at Alchemia Limited, where she was responsible for the management of the HyACT platform (clinical and regulatory), Alchemia’s late stage oncology product pipeline with multiple trials, including a global pivotal Phase III clinical trial. Jennifer also spent 5 years at Florigene, being responsible for Genetically Modified Organisms (GMO) regulatory framework, and 2 years at Davies Collison Cave Patent and Trademark Attorneys, managing client IP portfolios.

Jennifer commented on her appointment: “I am excited to be joining Clarity as Director of Quality and Regulatory Affairs at this exciting time when the Company is actively progressing its clinical trials in Australia and the U.S. with a number of important regulatory milestones down the track. I am looking forward to driving the regulatory process and developing a seamless regulatory framework that would leverage the existing achievements to progress the pipeline further.”

Clarity’s Executive Chairman Dr Alan Taylor said: “We are pleased to welcome Jennifer to our team and utilise her unique expertise in the biotechnology sector to strengthen Clarity’s regulatory function and ensure we keep achieving regulatory and clinical milestones with the ultimate goal of developing better treatments for children and adults with cancer. We are also excited to leverage Jennifer’s experience with the due diligence team of Viralytics during the Merck acquisition, which will be invaluable for preparing Clarity for any potential transactions that might arise in the future.”

Jennifer holds a Doctorate in genetics and molecular biology (Monash University).  Jennifer also previously held post-Doctoral research positions at Vanderbilt University (USA) and Monash University.

Click here to read full media release.

Media Contact

Dr Alan Taylor

Executive Chairman

Ph: +61 (0)413 871 165

E: ataylor@claritypharm.com

About Clarity

Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.



News & opinion

Member Directory